Gritstone bio Management

Management criteria checks 3/4

Gritstone bio's CEO is Andrew Allen, appointed in Aug 2015, has a tenure of 8.67 years. total yearly compensation is $2.68M, comprised of 23.2% salary and 76.8% bonuses, including company stock and options. directly owns 1.47% of the company’s shares, worth $1.27M. The average tenure of the management team and the board of directors is 3.1 years and 6.3 years respectively.

Key information

Andrew Allen

Chief executive officer

US$2.7m

Total compensation

CEO salary percentage	23.2%
CEO tenure	8.7yrs
CEO ownership	1.5%
Management average tenure	3.1yrs
Board average tenure	6.3yrs

Recent management updates

Recent updates

Gritstone bio: GRANITE Cancer Vaccine Data Overshadowed By Offering

Apr 07

Gritstone bio, Inc. (NASDAQ:GRTS) Analysts Just Slashed This Year's Revenue Estimates By 40%

Aug 14

Here's Why We're Not Too Worried About Gritstone bio's (NASDAQ:GRTS) Cash Burn Situation

May 26

Gritstone Oncology EPS beats by $0.41, beats on revenue

May 06

CEO Compensation Analysis

How has Andrew Allen's remuneration changed compared to Gritstone bio's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-US$138m
Sep 30 2023	n/a	n/a	-US$139m
Jun 30 2023	n/a	n/a	-US$130m
Mar 31 2023	n/a	n/a	-US$125m
Dec 31 2022	US$3m	US$620k	-US$120m
Sep 30 2022	n/a	n/a	-US$118m
Jun 30 2022	n/a	n/a	-US$116m
Mar 31 2022	n/a	n/a	-US$112m
Dec 31 2021	US$4m	US$589k	-US$75m
Sep 30 2021	n/a	n/a	-US$72m
Jun 30 2021	n/a	n/a	-US$70m
Mar 31 2021	n/a	n/a	-US$71m
Dec 31 2020	US$2m	US$569k	-US$105m
Sep 30 2020	n/a	n/a	-US$106m
Jun 30 2020	n/a	n/a	-US$107m
Mar 31 2020	n/a	n/a	-US$103m
Dec 31 2019	US$2m	US$533k	-US$94m
Sep 30 2019	n/a	n/a	-US$84m
Jun 30 2019	n/a	n/a	-US$75m
Mar 31 2019	n/a	n/a	-US$69m
Dec 31 2018	US$2m	US$475k	-US$65m
Sep 30 2018	n/a	n/a	-US$65m
Jun 30 2018	n/a	n/a	-US$56m
Mar 31 2018	n/a	n/a	-US$47m
Dec 31 2017	US$592k	US$436k	-US$41m

Compensation vs Market: Andrew's total compensation ($USD2.68M) is above average for companies of similar size in the US market ($USD673.68K).

Compensation vs Earnings: Andrew's compensation has been consistent with company performance over the past year.

CEO

Andrew Allen (57 yo)

8.7yrs

Tenure

US$2,675,168

Compensation

Dr. Andrew R. Allen, BM, BCh, MA, MRCP, M.D., Ph D., serves as Independent Director at Verge Analytics, Inc. since September 2021. He has also held clinical development leadership positions at Chiron Corpo...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Andrew Allen	Co-Founder	8.7yrs	US$2.68m	1.47% $ 1.3m
Erin Jones	Executive VP & COO	3.1yrs	US$1.33m	0.050% $ 43.2k
Karin Jooss	Executive VP and Head of Research & Development	3.1yrs	US$1.39m	0.35% $ 307.0k
Vassiliki Economides	Executive VP & CFO	2.8yrs	no data	0.033% $ 28.5k
James Cho	Chief Accounting Officer	3.3yrs	no data	0.058% $ 50.3k
George MacDougall	Director of Investor Relations & Corporate Communications	no data	no data	no data
Stacy Proctor	Executive VP & Chief People Officer	2.8yrs	no data	no data
Matthew Hawryluk	Executive VP & Chief Business Officer	8.4yrs	no data	0.073% $ 62.8k

3.1yrs

Average Tenure

51yo

Average Age

Experienced Management: GRTS's management team is considered experienced (3.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Andrew Allen	Co-Founder	8.7yrs	US$2.68m	1.47% $ 1.3m
Elaine Jones	Independent Chairman of the Board	4.6yrs	US$116.29k	0% $ 0
Steve Krognes	Independent Director	5.8yrs	US$87.29k	0% $ 0
Lawrence Corey	Independent Director	1.7yrs	US$112.08k	0% $ 0
Timothy Chan	Member of Scientific Advisory Board	6.8yrs	no data	no data
Eugene Zhukovsky	Member of Scientific Advisory Board	5yrs	no data	0% $ 0
Graham Lord	Member of Scientific Advisory Board	6.8yrs	no data	no data
Naiyer Rizvi	Independent Director & Member of Scientific Advisory Board	7.8yrs	US$76.79k	0% $ 0
James Gulley	Member of Scientific Advisory Board	6.8yrs	no data	no data
Alessandro Sette	Member of Scientific Advisory Board	6.8yrs	no data	no data
Shefali Agarwal	Independent Director	2.8yrs	US$74.79k	0% $ 0
Clare Fisher	Independent Director	2.3yrs	US$355.78k	no data

6.3yrs

Average Tenure

58yo

Average Age

Experienced Board: GRTS's board of directors are considered experienced (6.3 years average tenure).

Gritstone bio Management

Management criteria checks 3/4

Key information

Recent management updates

Gritstone Appoints Dr. Lawrence “Larry” Corey to Its Board of Directors, Effective from August 12, 2022

Less than half of directors are independent

Less than half of directors are independent

High number of new directors

High number of new directors

Executive VP & Chief Medical Officer notifies of intention to sell stock

Recent updates

Consensus revenue estimates decrease by 17%, EPS upgraded

Nature Medicine Publishes Interim Results from Gritstone Bio's Phase 1/2 Study of "Off-The-Shelf" Neoantigen Vaccine Platform (SLATE)

New minor risk - Market cap size

Gritstone bio: GRANITE Cancer Vaccine Data Overshadowed By Offering

Gritstone bio, Inc. has completed a Follow-on Equity Offering in the amount of $32.5 million.

Gritstone Bio, Inc. Announces Positive Preliminary Progression-Free Survival and Long-Term Circulating Tumor DNA (ctDNA) Data from Phase 2/3 Study of its Personalized Cancer Vaccine, Granite, Granite, Granite

Consensus revenue estimates decrease by 37%

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Share price stability

Price target decreased by 12% to US$8.80

Gritstone Bio Announces Update to Comparative Phase 2B Covid-19 Clinical Trial

Consensus revenue estimates fall by 40%

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Gritstone Bio, Inc. Announces Presentation of Results from Three Ongoing Phase 1 Studies Evaluating Its Self-Amplifying Mrna (Samrna) Vaccine Candidates Against Covid-19 (Part of the Company’s Coral Program) at IDWeek 2023

Price target increased by 20% to US$10.34

Gritstone bio, Inc. (NASDAQ:GRTS) Analysts Just Slashed This Year's Revenue Estimates By 40%

Price target increased by 20% to US$10.34

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Financial position

Consensus revenue estimates fall by 53%

Price target decreased by 14% to US$8.60

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Gritstone bio, Inc. to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$8.75

Gritstone bio, Inc. Announces Updated Overall Survival Results from Granite Phase 1/2 Study and Poster At Sitc 2022

Price target decreased to US$10.00

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$10.00

Gritstone bio, Inc. announced that it expects to receive $44.999991 million in funding from Redmile Group, LLC, Gilead Sciences, Inc., The Invus Group, LLC, Hercules Capital, Inc. and other investors

Gritstone bio: Early Data For SLATE Candidate Sets Up 2023 Catalyst

Gritstone bio, Inc. Presents Positive Initial Phase 2 Data in Late-Line Solid Tumor Patients Treated with KRAS-Directed Immunotherapy at ESMO 2022

Gritstone reaches six-month high on publication of data for cancer vaccine

Gritstone bio, Inc. Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of GRANITE, Individualized Neoantigen Vaccine for Solid Tumors

Consensus revenue estimates increase by 14%

Gritstone Appoints Dr. Lawrence “Larry” Corey to Its Board of Directors, Effective from August 12, 2022

Price target increased to US$16.00

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Gritstone bio announces $80M credit facility

Is Gritstone bio (NASDAQ:GRTS) In A Good Position To Invest In Growth?

Gritstone bio: Potential To Advance Colorectal Cancer Treatment

Gritstone bio, Inc.(NasdaqGS:GRTS) dropped from Russell 2500 Index

Gritstone bio: Investing In A Premium mRNA Technology At A Discounted Valuation

Gritstone Announces Results from Preclinical Study of Its Self-Amplifying Mrna (Samrna) Vaccine Against Sars-Cov-2 Published in Nature Communications

Gritstone Bio, Inc. Announces Updated Overall Survival Results in Advanced Colorectal Cancer Patients from Phase 1/2 Study of Granite and Trial in Progress Poster At Asco

Price target increased to US$16.00

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Gritstone bio, Inc. to Report Q1, 2022 Results on May 05, 2022

Price target decreased to US$14.67

Less than half of directors are independent

Some Analysts Just Cut Their Gritstone bio, Inc. (NASDAQ:GRTS) Estimates

Consensus revenue estimates fall by 57%

Full year 2021 earnings: EPS misses analyst expectations

We're Not Very Worried About Gritstone bio's (NASDAQ:GRTS) Cash Burn Rate

Gritstone: Why The Stock Fell On Positive Data

Gritstone Announces First Patient Enrolled for Phase 2/3 Trial Evaluating Individualized Neoantigen Vaccine GRANITE for First Line (1L) Maintenance Treatment of Metastatic, Microsatellite-Stable Colorectal Cancer (MSS-CRC)

Less than half of directors are independent

Gritstone Bio, Inc. Announces Positive Clinical Results from First Cohort of A Phase 1 Study (CORAL-BOOST) Evaluating A T Cell-Enhanced Self-Amplifying mRNA (SamRNA) Vaccine Against COVID-19

Gritstone bio, Inc Announces Omicron Variant of SARS-CoV-2 has Minimal Impact on the T Cell Epitopes (Targets) Contained within Gritstone’s Self-Amplifying mRNA COVID-19 Vaccines

Gritstone bio (NASDAQ:GRTS) Is In A Strong Position To Grow Its Business

Gritstone Poised To Dominate mRNA Market

Third quarter 2021 earnings released: US$0.36 loss per share (vs US$0.69 loss in 3Q 2020)

Price target decreased to US$20.33

Gritstone Announces Dosing of First Volunteer in Trial Evaluating Self-Amplifying mRNA as a COVID-19 Vaccine Booster and Immunogenicity Enhancer

Gritstone Bio, Inc. Announces Dosing of First Solid Tumor Patient with Optimized SLATE “Off-the-Shelf” Mutant KRAS-directed Neoantigen Immunotherapy in Phase 2 Clinical Trial

Gritstone to Host Data Update on Neoantigen Oncology Programs for the Treatment of Solid Tumors During ESMO 2021

Second quarter 2021 earnings released: US$0.33 loss per share (vs US$0.69 loss in 2Q 2020)